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Introduction. Tenosynovial giant cell tumors (TGCT) emerge from the synovium and can behave aggressively. Surgical resection
is the standard treatment. However, up to half of the patients with diffuse type show recurrences. Several additional treatments
have been applied to reduce recurrences; none of these treatments was proven to be superior to surgical resection solely.This article
describes the results of additional cryosurgery to surgical resection.Materials andMethods. We retrospectively evaluated 141 TGCT
patients, between 1999 and 2007. Twelve patients had additional cryosurgery.The knee (𝑛 = 8), hip (𝑛 = 2), ankle (𝑛 = 1), and elbow
(𝑛 = 1) were affected. Primary outcome variables were treatment indications, recurrences, and complications. Results. Indications
for additional cryosurgery were extended disease, bone involvement, and locations that are difficult to surgically get disease-free
such as cruciate ligaments. Five patients had recurrent disease, all of which had prior treatments. None of the primary treated
patients had recurrent disease. One patient had a deep infection.Discussion. Cryosurgery may serve as an additional treatment for
diffuse TCGT in selected cases. However, because of the small number of patients and the heterogeneous group we could not prove
an advantage of additional cryosurgery over surgical resection only. Cryosurgery should be considered for further evaluation in a
prospective study. If there is any effect it would be helpful, especially in patients with multiple TGCT recurrences.
1. Introduction
The tenosynovial giant cell tumor (TGCT), formerly known
as pigmented villonodular synovitis (PVNS), is a rare prolif-
erative disorder originating from the synovial membrane. Its
annual incidence is described as 1.8 per million US citizens
[1]. TGCT has a neoplastic origin, with a reactive component
based on specific genetic changes [2, 3]. Although TGCT can
behave locally aggressive, it is considered a benign disorder
[2]. Two subtypes have been described, (1) the less aggressive,
localized form (LTGCT), which usually is a single nodular
lesion, and (2) the diffuse form (DTGCT), which usually
affects the whole joint and frequently recurs (14–55%) [4, 5].
The knee (75%) is the most frequently affected joint, followed
by the hip, ankle, elbow, and other synovial joints [2].
The recommended treatment for TGCT is surgical resec-
tion of all affected tissue [4]. Incomplete resection ormultiple
treatments can result in functional impairment [6]. With
extended or recurrent disease, several additional treatments
(e.g., External Beam Radiotherapy (EBRT), radiosynovec-
tomy, and immune- and targeted therapy) have been applied
to reduce recurrence rates [4]. None of these treatments was
proven to be superior to surgical resection on its own, which
makes aggressive, persistently recurrent TGCT difficult to
cure [4].
Cryosurgery, in the form of liquid nitrogen spray, is
widely used as an additional treatment for various bone tu-
mors [7]. In order to try to reduce recurrence rates, we
started using cryosurgery as an additive treatment to surgical
resection of TGCT in selected cases. Mohler and Kessler [8]
reported on the successful treatment of three TGCT patients
through surgical synovectomy combined with cryosurgery.
To the best of our knowledge, there are no other publications
that describe cryosurgery as an additive treatment to surgical
resection, in the treatment of TGCT.
We retrospectively evaluated TGCT patients treated with
cryosurgery in addition to surgical synovectomy, with respect
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to the indication for additional treatment(s), the number of
recurrences, and complications.
2. Materials and Methods
We retrospectively searched pathologic and radiologic re-
ports in the hospital database with the keywords “pigmented
villonodular synovitis”, “local tenosynovitis”, and “giant cell
tumor of the tendon sheath”. Between 1985 and 2014, 141
TGCT patients were identified; 48 (34%) with localized
and 93 (66%) with diffuse disease. According to operative
reports, cryosurgery was used in 12 patients, between 1999
and 2007. Clinical, pathological, radiological, treatment, and
follow-up information was obtained from medical records.
The study protocol (CMO2015-1915) was assessed by our
institutional review board (the research ethics committee of
the Radboud University Nijmegen Medical Center) and was
carried out in Netherlands in accordance with the applicable
rules concerning the review of research ethics committees
and informed consent.
There was no protocol for the use of additional cryosur-
gery. All patients with extended or recurrent disease were
discussed in a multidisciplinary team (medical oncology,
radiotherapy, surgical oncology, and orthopedic surgical
oncology). However, eventually it was the surgeon’s call for
each individual case whether or not to use cryosurgery. In
the 12 patients who received additional cryosurgery the knee
(𝑛 = 8), hip (𝑛 = 2), ankle (𝑛 = 1), and elbow (𝑛 = 1) were
affected. All diagnoses were histologically confirmed. One
patient (elbow) had localized disease; all other patients had
diffuse disease. The mean age at the time of cryosurgery was
39 (range 21–61) years. All patient characteristics are listed in
Table 1.
Cryosurgery was used in addition to a surgical synovec-
tomy. After complete removal of the affected tissue, the non-
cartilaginous surface of the joint (synovium, joint capsule,
and bone) was treated with three cycles of liquid nitrogen
spray. All frozen tissue got to at least −50∘C. Spontaneous
thawing warmed the tissue up to 20∘C. After three cycles
of rapid cooling and spontaneous thawing the entire wound
was lavaged with sodium hyponitrite to prevent seeding of
tumor cells. A healthy circulation (no use of a tourniquet) is
important to protect neurovascular structures and the skin
[7, 9]. To the best of our knowledge there is no literature
available yet on costs of cryosurgical treatment. However, we
would estimate a maximal extra surgical time of 15 minutes
(i.e., three times 5 minutes, quick freeze, and slow thawing).
The materials needed for cryosurgery are a little container
and temperature sensors. Liquid nitrogen costs 10 euro cents
a liter and we use less than a liter for one patient. Details of all
received treatments are listened in Table 1.
Between 1985 and 2014 our follow-up protocol has
changed from an intensive follow-up with 3 monthly visits,
including a MRI every 6 months, to only a single clinical
follow-up visit 3months postoperativelywith additional visits
when clinical symptoms appear, a “wait and see policy.”
Outcomes were the indications for additional cryosur-
gery, recurrent disease, and complications. To be able to for-
mulate indications for cryosurgery we scored extra-articular
disease, large expansion (described in operative reports as
extensive or bulky disease or when two or more compart-
ments of the knee were involved), bone involvement, and
involvement of the cruciate ligaments. Local recurrent disease
was defined as histological proven recurrent disease.
Descriptive statisticswere used to summarize the data.No
further analyses were performed because of the small number
and diversity of patients.
3. Results
Of the 141 identified TGCT patients, 12 patients received
additional cryosurgery. In the 129 patients without additional
cryosurgery, 82 had diffuse disease. Fourteen of these patients
had no treatment at our tertiary center. In 68 patients treated
at our center the knee (𝑛 = 59), hip (𝑛 = 3), ankle (𝑛 = 5),
and elbow (𝑛 = 1) were affected. Three patients were lost to
follow-up. The mean time from first treatment to follow-up
was 10 (range 0.6–41) years.
3.1. Indications for Cryosurgery. In the 12 cryosurgical pa-
tients, five had primary disease and seven had prior treat-
ments (1–3 previous treatments). The mean time from
diagnose to cryosurgical treatment was 4.5 (range 0.5–6.3)
years. In 10 out of 12 patients, the entire intra-articular
space was affected with extension in surrounding structures,
such as bone, ligaments, fat, and muscle tissue. All were of
diffuse type TGCT. Seven of these patients had extra-articular
disease. The cruciate ligaments of the knee were involved in
6 out of 8 patients. In 7 out of 12 patients (𝑛 = 4 knees, 𝑛 = 2
hips, and 𝑛 = 1 ankle) there was bone involvement. Bone
involvement and extended disease were reported to be indi-
cations for additional cryosurgery to surgical synovectomy.
In one patient with localized disease of the elbow, we
retrospectively did not find the considerations for additional
cryosurgery. Probably the surgeon wanted to minimize the
chance on recurrent disease in this location.
In patients with DTGCT of the knee (𝑛 = 59), 19 patients
had extra-articular disease, 4 patients had bone involve-
ment, 52 patients had intracondylar involvement, and 55 had
extended disease or a combination of two, three, or all four of
these features. All five ankles had extended diseasewith extra-
articular involvement, and one of these patients also had bony
involvement.
3.2. Recurrences. The mean follow-up after cryosurgery was
7.7 (range 5.5–14.9) years. Five patients with the diffuse
subtype developed recurrent disease after cryosurgery, at
a mean time of 2.8 (range 0.7–9.0) years. All recurrences
were diagnosed on MRI, which was performed when clin-
ical symptoms of any kind in or nearby the affected joint
presented. Four were also histologically confirmed. None of
these five patients had primary disease; they already had
recurrent disease at the time of cryosurgical therapy. One
patient with recurrent disease received EBRT following initial
cryosurgery. Another patient received a total hip arthroplasty
(THA) during the same surgical procedure.
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Table 1: Demographics, previous recurrences, and detailed description of treatments received before or in combination with additional
cryosurgery.
Patient
ID Sex
Age (at time of
surgery) Localized/diffuse
Previous
recurrences
Follow-up before
cryosurgery (years)
All treatments received
1st 2nd 3rd 4th
Knee
1 F 61 Dt-GCT 3 6.3 SE SE tSE tSE + cryo+ EBRT
2 M 58 Dt-GCT 2 9.7 Yt SE tSE + cryo+ EBRT
3 F 46 Dt-GCT 2 3.2 SE SE SE + cryo
4 M 51 Dt-GCT 0 0.3 tSE + cryo
5 F 25 Dt-GCT 1 3.0 tSE SE + cryo
6 F 49 Dt-GCT 0 0.1 SE + cryo
7 M 31 Dt-GCT 2 4.9 tSE SE SE + cryo
8 F 31 Dt-GCT 0 0.0 tSE + cryo
Hip
9 M 44 Dt-GCT 2 0.5 tSE SE SE + THA+ cryo
10 F 20 Dt-GCT 2 4.0 SE Yt SE + THA+ cryo
Ankle
11 M 34 Dt-GCT 0 0.0 SE + cryo
Elbow
12 F 21 Lt-GCT 0 0.7 SE + cryo
F: female, M: male, SE: surgical synovectomy, tSE: two-stage synovectomy (anterior and posterior compartment of the knee in two separate procedures), Yt:
yttrium radiosynovectomy, EBRT: external beam radiation therapy, cryo: cryosurgery, follow-up before cryosurgery: the time from diagnose until the use of
cryosurgery in years, and THA: total hip arthroplasty.
Three out of five patients with recurrent disease after
cryosurgery developed a second or even third recurrence.
Treatments following these recurrences are listed in Table 2.
All four recurrences in patients with TGCT of the knee
occurred within 2 years (9–22 months) after treatment.
These patients had extended disease with involvement of the
cruciate ligaments. In two patients with recurrent disease
there was extra-articular disease and in one there was bone
involvement. In the four knee patients without recurrences
(of whom three were primary treated and one was treated
with additional EBRT following cryosurgery), three had
extended disease with bone involvement.
In the two patients with TGCT of the hip, one recurrence
occurred nine years after cryosurgery. It was the third
recurrence since onset of disease. At the time of cryosurgery,
the acetabulum was affected by TGCT. Both patients also
received a total hip arthroplasty for joint destruction by
extended disease combined with secondary osteoarthritis. In
both ankle and elbow, no recurrences were seen.
In patients with diffuse type disease whomdid not receive
additional cryosurgery 30 (44%) had recurrent disease. The
mean time to first recurrence was 4.7 (range 0.7–27) years. All
referred knee patients (𝑛 = 26) had recurrent disease. Nine
(34.6%) of these patients developed another recurrence after
treatment at our center in 1.7 (range 0.7–4.4) years. In primary
treated knee patients 16 (55%) had recurrent disease in 6.4
(range 1–27) years.
Twenty-seven patients (40%) had extra-articular disease,
6 (9%) had bone involvement, 52 (77%) had involvement
of the cruciate ligaments, and in 64 (94%) patients there
was extended disease or a combination of two, three, or
all four of these features. For example, in the 27 patients
with extra-articular disease 6 had bone involvement, 18 had
affected cruciate ligaments, and all 27 had extended disease.
Eighteen of these patients had recurrent disease in 7 (0.8–
17) years of follow-up. The time to first recurrence was 1.9
(0.7–4.1) years. And 11 recurrences appeared after treatment
at our center. All 6 patients with bone involvement had extra-
articular disease and extended disease, including 4 patients
with affected cruciate ligaments. Five of these patients had
recurrent disease in 11 (2–17) years of follow-up. The time
to first recurrence was 1.8 (1.2–3.2) years. Three recurrences
appeared after treatment at our center.
Of five patients with TGCT in the ankle 4 had recurrent
disease, two of which were primary treated patients. The
mean time until first recurrence was 2.7 (1.2–4.1) years.
3.3. Complications. Two complications were reported in the
cryosurgical group (Table 2): a hip dislocation direct after
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arthroplasty, which was closed reduced, and a deep infection
of the knee, three months after surgery, which was treated
with surgical debridement and antibiotics.
4. Discussion
TGCT is difficult to cure; in particular, the diffuse subtype
frequently recurs. The treatment of first choice is surgical
resection of all affected tissue. However, with extended
and/or extra-articular disease, bone involvement, or disease
at key locations inside the joint (ACL, PCL, and collateral
ligaments), resection of all affected tissue can be difficult to
achieve. Various treatments (e.g., radiosynovectomy, EBRT,
and immune- or targeted treatment) have been used, without
the desired results [4]. We retrospectively evaluated the effect
of additional cryosurgery in the treatment of TGCT.
We found that indications of cryosurgery in addition to
surgical resection for TGCT were the presence of extended,
extra-articular disease, affected bone, or locations surgically
difficult to get disease-free, such as the cruciate ligaments.
Furthermore, no recurrent disease was observed in patients
primary treated with surgical synovectomy combined with
cryosurgery. In patients known with recurrent disease addi-
tional cryosurgery was not effective.
Various indications were described for additional ther-
apies in the treatment of TGCT [4]. The indications found
for cryosurgery were similar to those considered for EBRT,
except for patients with involvement of the neurovascular
bundle. Cryosurgery is contraindicated in these patients.
Effectiveness of radiosynovectomy in the treatment of TGCT
is not proven and does not cover the extra-articular space
[5]. Therefore, it is not indicated in patients with extended
disease. Immunotherapy is not validated yet for the treatment
of TGCT; however it has been applied in patients with
extended disease [10, 11]. For the use of targeted therapy
in the treatment of TGCT, only small case studies and one
retrospective cohort (29 patients) are published so far [3, 12–
14]. Due to the rapid relapse after discontinuation and severe
side effects of targeted therapy, these treatments are only
recommended for patients with surgical unresectable disease
or multiple recurrences that produce clinical and functional
impairment [12]. Other systemic treatments are individually
available in trial settings [15].
Additional cryosurgery was not used after 2007 for
different reasons: less extreme TGCT cases were presented
the last years. The surgeon who often used cryosurgery for
TGCT retired. Others preferred a more throughout resection
of affected tissue. There were definitely no adverse effects of
cryosurgery that made us stop using it.
The number of recurrences in DTGCT with or without
the use of cryosurgery were similar, respectively, 45% after
2.8 years and 44% after 4.7 years. However, retrospectively
it is difficult to determine if the patients in the cryosurgical
group had worse disease compared to the other patients. In
the cryosurgical group there was 90% extended disease, 64%
extra-articular disease, and 64% bone involvement and in
88% the cruciate ligaments were involved. The others had
94% extended disease, 40% extra-articular disease, 6% bone
involvement, and 77% involvement of the cruciate ligaments.
In both groups there was a great difference in recurrences
between referred patients and primary treated patients.There
were five (71%) recurrences after cryosurgery, in patients
with prior treatments. Two out of seven patients with bone
involvement had recurrent disease. None of the primary
treated TGCT patients had recurrences after surgical syn-
ovectomy with cryosurgery. In the patients not treated with
cryosurgery all referred knee patients showed recurrent
disease of which 35% had recurrent disease after treatment at
our center.Therewere 55% recurrences in the primary treated
knee patients.
Mohler and Kessler [8] described the use of cryosurgery
in addition to surgical synovectomy in three patients (25–31
years of age) with TGCT of the knee. Two of these patients
were diagnosedwith recurrent disease. Cryosurgerywas used
during their third treatment. The other patient had primary
disease. Two patients had extended disease. But, no details of
bone involvement or involvement of the cruciate ligaments
were described. No recurrent disease was found after 14–
31 months of follow-up. However, TGCT recurrences are
described up to 14 years later [16].
Although cryosurgery is uncommon in the treatment of
TGCT, it has been described for orthopedic oncologic dis-
eases [7]. Reported complications as a result of cryosurgery
are postoperative fractures (5–30%), infections (4%), tran-
sient nerve palsies, and gas-embolisms (0.3%) [7]. Also,
damage to surrounding structures, such as the epiphysis
and cartilage, has been described. In case of TGCT, the
chance on fractures will be negligible though the intra-
articular location. However, for this reason there might be an
increased risk on damage to the joint cartilage. Furthermore,
in TGCT the cartilage is often already damaged due to the
disease itself or to the multiple prior treatments. None of
these complications were found in this study. However, one
patient with recurrent disease after cryosurgery received a
total knee arthroplasty for secondary osteoarthritis. Also, a
postoperative dislocation of the hip and a deep infection of
the knee three months after surgery occurred.These could be
general complications after surgery; however, increased risk
on infections have been described for cryosurgery [7].
Abbreviations
TGCT: Tenosynovial giant cell tumor
LTGCT: Localized tenosynovial giant cell tumor
DTGCT: Diffuse tenosynovial giant cell tumor
EBRT: External beam radiation therapy
THA: Total hip arthroplasty
TKA: Total knee arthroplasty.
Additional Points
Limitations. It is very difficult to produce a large volume
study on treatment effects in a rare disease such as TGCT.
For the subgroup of patients with extended disease, this is
even more difficult. Therefore the study is limited by its
retrospective character and the small number of patients.
However, detailed information on received treatments was
available and carefully described. Furthermore, some patients
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had other additional treatments next to cryosurgery, such
as EBRT or arthroplasty what could have influenced our
results. However, this was seen in both patient groups with
and without recurrent disease. Despite these limitations,
this article provides cautious insight for a possible role of
cryosurgery in the treatment of TGCT. A prospective study
with clear indications should follow to show if there is a role
for cryosurgery in a subgroup of TGCTpatients.We conclude
that cryosurgery may serve as an additional treatment for
diffuse TCGT in selected cases. However, because of the
small number of patients and the heterogeneous group we
could not prove an advantage of additional cryosurgery over
surgical resection only. Cryosurgery is a cheap, easy, and
relative harmless technique that should be considered for
further evaluation in a prospective study with a sufficiently
large number of patients, clear indications, and a proper
control group. If there is any effect it would be helpful,
especially in patients with multiple TGCT recurrences.
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